BiotechTube
Vascudyne

Vascudyne

Stillwater, United States· Est.
vascudyne.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

Vascudyne is a private, pre-revenue tissue engineering company pioneering the development of fully biological, regenerative vascular grafts and soft tissue biomaterials. Its core technology platform is designed to produce non-immunogenic human tissues for cardiovascular, vascular, neurological, wound care, and aesthetic applications. The company is currently advancing its investigational allograft technology toward clinical trials, supported by a team and advisors with deep expertise in medical device development and regulatory pathways for Class III implants.

CardiovascularVascular SurgeryWound CareAesthetic Medicine

Technology Platform

A tissue engineering platform designed to grow and engineer 100% biological, regenerative, and non-immunogenic human tissues in various shapes and sizes for multiple medical applications.

Funding History

3
Total raised:$20M
Grant$2M
Series A$15M
Seed$3M

Opportunities

The primary opportunity lies in addressing multi-billion dollar unmet needs in cardiovascular surgery, particularly for pediatric patients requiring growth-capable grafts and for dialysis patients needing durable access.
A successful 100% biological, non-immunogenic graft could displace current synthetic and animal-tissue options, capturing significant market share.
The platform's extension into soft tissue reconstruction offers additional revenue potential in wound care and aesthetics.

Risk Factors

Major risks include the high technical difficulty of scaling production of consistent, robust engineered human tissue, the long and uncertain regulatory pathway for Class III devices, and the challenge of competing against established, lower-cost graft alternatives.
Financial risk is also high as a pre-revenue company dependent on external funding to reach clinical milestones.

Competitive Landscape

Vascudyne competes in the vascular graft and heart valve space against large medtech players like Medtronic, Abbott, and Edwards Lifesciences, which offer synthetic grafts and animal-tissue valves. It also faces competition from other tissue engineering and regenerative medicine companies (e.g., Humacyte with its bioengineered human acellular vessel). Vascudyne's key proposed differentiator is a fully biological, non-immunogenic, and regenerative tissue, a claim that, if proven, would set it apart from both synthetic and decellularized competitor products.

More companies in Regenerative Medicine →More companies in United States →